Naloxone
Brand names: Narcan, Prenoxad, Nyxoid
A short-acting opioid receptor antagonist used as the emergency antidote for opioid overdose and to reverse opioid-induced respiratory depression.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Naloxone competitively displaces opioids from mu (and other) opioid receptors, rapidly reversing opioid effects including respiratory depression and sedation.
Prescribing in practice
- Its duration of action is often shorter than that of the opioid being reversed, so repeated doses or an infusion and continued observation are essential to prevent re-sedation.
- In opioid-dependent patients reversal can precipitate an acute withdrawal syndrome, so titrate to restore adequate breathing rather than full consciousness.
- It is ineffective against respiratory depression caused by non-opioid agents and gives no benefit where opioids are not involved.
Monitoring
Monitor respiratory rate, conscious level and oxygen saturation closely and for a prolonged period after administration because of the risk of recurrent respiratory depression.
Counselling the patient
- Anyone given naloxone for an overdose must be kept under observation, as the opioid effect can return as the antidote wears off.
- Family and carers should know how to recognise overdose and call emergency services even after naloxone is given.
Evidence & guidelines
Naloxone is the recognised standard antidote for opioid toxicity in resuscitation and toxicology guidance, including take-home naloxone programmes for overdose prevention.
Reference: NICE; TOXBASE; NPIS; SIGN Opioid Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Morphine Milligram Equivalents (MME) Calculator · Pain / Opioids
- Opioid Conversion / Equianalgesic Guide · Pain Management
- Numeric Rating Scale (NRS) Pain Assessment and Management · Pain Management
- Finnegan Neonatal Abstinence Scoring Tool (FNAST) · Neonatal Abstinence Syndrome
- Modified Finnegan Neonatal Abstinence Score (NAS) · Neonatal
- Withdrawal Assessment Tool (WAT-1) for Paediatric Iatrogenic Withdrawal · Critical Care
- MorphineRecommendedAnalgesic
- Tramadol hydrochlorideRecommendedAtypical opioid (μ-agonist + SNRI)
- Methadone hydrochlorideRecommendedLong-acting synthetic opioid
- Difficult Airway Algorithm (DAS) · DAS 2015; Royal College of Anaesthetists
- Major Haemorrhage Protocol · NICE NG24; UK MHP guidelines
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
Featured in these MRCEM clinical pathways
Naloxone is a core drug in the following exam-focused workups on our sister siteReviseMRCEM.
MRCEM Primary / Intermediate / OSCE candidates: each pathway includes exam-style questions, RCEM/NICE citations, and FAQ summaries.